Established in the mid-1980s, QIAGEN, a life science and high technology company has been instrumental in providing a simpler and safer way for laboratories across different industries to handle the painstaking tasks of unfolding the mysteries of genomes. QIAGEN provides Sample to Insight solutions that help their customers to gain valuable molecular insights from biological samples containing the building blocks of life. “A very promising pipeline of future applications and assays will add exciting value to our customers, including capabilities and assays in companion diagnostics and oncology, as well as in quantitative analysis and immunoassay testing,” begins Peer M. Schatz, CEO of QIAGEN. Having served in the industry for more than a decade, QIAGEN has established itself as a trailblazer in the biotechnology solutions with their advanced molecular testing solutions that enable customers to conquer scientific frontiers. QIAGEN delivers a range of products that meet the special requirements of more than 500,000 customers worldwide to access and analyze the content from biological samples for breakthroughs in biomedical research, drug development, and molecular testing.
Schatz, the son of famous biochemist Gottfried Schatz, who co-discovered mitochondrial DNA, is stirring a revolution in the biotechnology landscape.
His expertise in molecular biology and life sciences has advanced QIAGEN’s strategic focus on sample and assay technologies in the molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharma and biotech companies) and academia (life sciences research) markets. QIAGEN’s comprehensive solutions can be implemented by diagnostic laboratories, academic research institutions, pharmaceutical and biotech companies to achieve outstanding success and breakthroughs in research and drug development.
We provide sample to insight solutions that will add exciting value to our customers to gain valuable molecular insights from biological samples containing the building blocks of life
QIAGEN’s solutions for research studies span from clinical sample processing all the way to downstream molecular analysis for assays. By providing sample and assay technologies, QIAGEN allows scientists to isolate and process DNA, RNA, and proteins from blood, tissue, and other biological materials. As assay technologies provide clear visibility of biomolecules, researchers can efficiently analyze the genetic materials extracted from samples to develop various products. The company also offer industry-leading applications for the analysis, interpretation, and reporting of biological data.
Having more than 20 years of experience in handling, stabilization, and purification of different analytes, QIAGEN team provides complete matching solutions to standardize all steps of the workflow. This ensures comparability and reproducibility of data in clinical case-controlled and population-based studies, facilitating biomarker in the development of diagnostics and therapeutics. With the help of QIAGEN’s bioinformatics software and knowledge bases, customers can interpret data to report relevant and actionable insights.
The Core Concept of NGS
To strengthen their value proposition, QIAGEN recently partnered with Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System. The GeneReader NGS System provides the first true Sample to Insight NGS workflow for laboratories worldwide to take advantage of the power of NGS technology. “We are excited to partner with Natera, a global market leader in non-invasive cell-free DNA genetic testing,” says Schatz. Through this strategic partnership, QIAGEN is planning to offer assays that provide significant clinical and economic value backed by extensive validation data and large clinical studies. The company intends to make these assays available to all the laboratories around the world that are very eager to bring in-house genetic testing across several applications, including prenatal screening. He adds, “The addition of these assays, along with Natera’s Constellation software, will substantially increase the system’s value and utility for a broader range of customers beyond the current menu focused on oncology.”
Reaching New Heights
QIAGEN is on track to achieve the 2018 targets for accelerating sales and adjusted earnings. The company is progressing quickly to achieve their 2020 mid-term growth targets. The company’s expansion plans for 2018 include the rapid scale-up of the new Enterprise Genomics Services, which will help customers to accelerate and de-risk the development of new gene panels that are essential for the migration of biomedical findings from discovery to implementation in clinical healthcare. “We also have extensive growth plans for our successful GeneReader system with the introduction of the new, proprietary third-generation chemistry and a series of new gene panels based on our proprietary Digital NGS technology,” concludes Schatz.